Inhibikase Therapeutics, Inc.
corporate_fare Company Profile
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for IKT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-26, rated 8/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for IKT spans 8-K, 10-Q, PRE 14A, 10-K.
Recent high-impact activity:
- Inhibikase Swaps Auditors, Dropping CohnReznick for Deloitte
- Inhibikase Q2 Loss Widens to $19.6M as Phase 3 PAH Trial Costs Surge; $50M ATM Sale to RA Capital Closed in July
- Inhibikase Q2 Loss Hits $19.6M as Trial Costs Mount
- Inhibikase Restructures RA Capital Stake: 18M Shares Exchanged for Pre-Funded Warrant
- Inhibikase Therapeutics' IKT-001 Secures FDA Orphan Drug Designation for PAH
Financial Snapshot
Short Interest & Short Volume
28.59 days to coverFINRA reported short interest of 19,428,875 shares in IKT as of the October 30, 2026 settlement, a 1.0% decrease from the prior period — about 28.6 days to cover at its recent average daily volume. On November 20, 2026, 60.9% of IKT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.